Parks Diane L.
Known title: DirectorCIK: 0001781026
Associated companies
Transaction History
| CELU | ▲ Buy | Grant | 30,000 | $0 | 1/12/2026 | View on chart |
| CELU | ▲ Buy | Grant | 125,000 | $0 | 12/29/2025 | View on chart |
| CELU | ▲ Buy | Grant | 67,416 | $0 | 12/19/2025 | View on chart |
| CELU | ▲ Buy | Grant | 61,539 | $0 | 11/19/2025 | View on chart |
| CELU | ▲ Buy | Grant | 67,416 | $0 | 12/19/2024 | View on chart |
| CELU | ▲ Buy | Grant | 199,921 | $0 | 6/14/2023 | View on chart |
| CELU | ▲ Buy | Grant | 36,145 | $0 | 7/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Celularity Q1 2027 EPS Up, Announces Partner & Board Member
Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.
Celularity Q1 2027 EPS Up, Announces Partner & Board Member. Celularity posted a first‑quarter 2027 earnings per share of $0.02, up from a loss of $0.84 a year earlier, while sales fell to $3.85 million from $11.43 million. The company will open the Fontaine Vitale facility with its strategic partner and added Naveen Jain to its board. It also closed a $10 million private placement of senior secured convertible notes and warrants, part of a $28 million recapitalization plan.